Publications

Journal Article Epublish
Electronic publication date
November 8, 2026

View on Pubmed.gov 42998120 | View on doi.org 10.1007/s00415-...

GLP-1 receptor agonist use in patients with minor stroke is associated with lower risk of post-stroke dementia.

Search for publications in this journal J Neurol

Abstract

BACKGROUND

Minor ischemic stroke is associated with increased risks of post-stroke dementia independent of stroke recurrence, yet there are no guideline-recommended therapies targeted at cognitive outcomes. Glucagon-like peptide - 1 receptor agonists (GLP-1RAs) have been shown to be associated with lower risk of dementia among diabetes patients; however, their effect on cognitive outcomes among minor stroke patients is largely unknown.

METHODS

This retrospective cohort study used de-identified electronic health record data from the TriNetX US Collaborative Network (2016-2025). Adult patients with minor ischemic stroke (NIHSS ≤ 5 and non-disabling) were included. Patients with prior intracranial hemorrhage, mood disorders, anxiety disorders, cognitive impairment, or dementia were excluded. GLP-1RA use was defined as a prescription prior to or within 3 months of stroke diagnosis. After 1:1 propensity score matching on 75 baseline characteristics, outcomes were assessed over a 5 year follow-up using Kaplan-Meier analysis and Cox proportional hazards models.

RESULTS

After propensity score matching, 1,425 patients per group were analyzed. Mean age was 60.7 years, with diabetes present in 92.7% and mean HbA1c of 8.7%. GLP-1RA use was associated with a 48% lower hazard of post-stroke dementia (3.4% vs. 7.0%, HR 0.52 [95% CI 0.37-0.74]) and a 31% lower hazard of other neurocognitive complaints (17.2% vs 25.6%, HR 0.69 [95% CI 0.59-0.81]) over 5 years. GLP-1RA use was also associated with reduced mortality (4.4% vs. 8.8%; HR 0.57 [95% CI 0.42-0.77]) and major ischemic stroke (1.5% vs. 2.7%; HR 0.59 [95% CI 0.35-1.01]). No significant difference in intracranial hemorrhage rates was observed.

CONCLUSIONS

Among this cohort of minor ischemic stroke patients mostly with concomitant diabetes, GLP-1RA use was associated with significantly reduced risks of post-stroke dementia and other neurocognitive complaints. These findings support prioritizing GLP-1RA use for diabetic patients who suffered minor ischemic stroke. Prospective trials are warranted to confirm causality and determine optimal implementation.

References

Feigin VL, Brainin M, Norrving B et al (2025) World Stroke Organization: global stroke fact sheet 2025. Int J Stroke 20(2):132–144. doi.org

Amarenco P, Lavallée PC, Monteiro Tavares L et al (2018) Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med 378(23):2182–2190. doi.org

Park TH, Hong KS, Choi JC et al (2013) Validation of minor stroke definitions for thrombolysis decision making. J Stroke Cerebrovasc Dis 22(4):482–490. doi.org

Nicolas K, Levi C, Evans TJ et al (2020) Cognition in the first year after a minor stroke, transient ischemic attack, or mimic event and the role of vascular risk factors. Front Neurol 11:216. doi.org

Conflict of interest statement

Declarations. Conflicts of interest: DAL is consultant for iSchemaView RapidAI and DocPanel Technologies, and is Scientific advisory board member for Upstream Vision. VSY is consultant for iSchemaView, RapidAI. DJA reports securities holdings in Von Vascular, Inc, and compensation from Johnson and Johnson International, Stryker Corporation, Medtronic USA, Inc, and MicroVention, Inc, for consultant services. DG receives research grants from the Focused Ultrasound Foundation, NIH, University of Maryland Medical Center, and Microvention, and is a consultant for Navigantis. Other authors have no relevant disclosures to report. Ethical approval: The study protocol was reviewed by the Institutional Review Board of West Virginia University (Reference: #STUDY00000320), which also granted a waiver of informed consent owing to the retrospective design and exclusive use of anonymized patient data. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki for research involving human participants. Guarantor: Dhairya A Lakhani, MD.

MeSH

Specialties

Substances

Copyright

© 2026. Springer-Verlag GmbH Germany, part of Springer Nature.